Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Gene Therapy
Scientists at Got-A-Gene AB detail research in gene therapy
February 24th, 2009
Researchers detail in 'Re-targeted adenovirus vectors with dual specificity; binding specificities conferred by two different Affibody molecules in the fiber,' new data in gene therapy. According to recent research from Sweden, "Vectors based on Adenovirus type 5 (Ad5) are among the most common vectors in cancer gene therapy trials to date. However, for increased efficiency and safety, Ad5 should be de-targeted from its native receptors and re-targeted to a tumor antigen." "We have described earlier an Ad5 vector genetically re-targeted to the tumor antigen HER2/neu by a dimeric version of the Affibody molecule ZH inserted in the HI-loop of the fiber knob of a coxsackie...
Source: Cancer Weekly (2009-02-24)
|
